IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the United States Patent and Trademark Office (USPTO) issued three new U.S. Patents, Nos. 9,040,770, 9,040,039 and 9,040,038, which expand the scope of protection of the four previously issued U.S. patents covering its retinal pigment epithelium (RPE) transplant technology. These three new patents extend protection to
WATERFORD, N.Y.–(BUSINESS WIRE)–Momentive to present two technical posters highlighting the benefits of the new OphthaSil* silicone polymer product portfolio for the contact lens industry.
TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ: 4573) We are pleased to announce that the phase I single-dose clinical trial for the new molecular entity RTU-1096 has been completed. RTU-1096 is a vascular adhesion protein-1 (VAP-1) inhibitor having anti-…
TOKYO–(BUSINESS WIRE)–PENTAX Medical Launches Splash M-Knife, The New Multi-Functional ESD Device
東京–(BUSINESS WIRE)–HOYA株式会社PENTAXライフケア事業部 新製品『PENTAX Medical 高周波ナイフ DN-Dシリーズ （愛称Splash M-Knife）』を販売開始
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, a leading eyewear designer and marketer, is launching a nationwide consumer ad campaign for its Foster Grant® brand featuring its new spokesperson, popular actress and musician Kat Graham. Kat joins iconic actress and author Brooke Shields as the latest celebrity featured in the brand’s famous “Who’s that behind those Foster Grants®” campaign, which will feature ads on national network cable television as well as a digital component, slated
MUNICH–(BUSINESS WIRE)–EMA grants orphan drug designation for Isarna’s ISTH0036, a LNA-modified antisense oligonucleotide targeting TGF-β2, for the prevention of scarring post trabeculectomy in glaucoma.
WAKEFIELD, Mass.–(BUSINESS WIRE)–Optikos CEO, Stephen D. Fantone, receives Rochester Distinguished Scholar Award at the University’s 2015 Doctoral Ceremony.
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. Dr. West will pr…
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare study: comprehensive eye exams can help re-engage patients into care for certain chronic conditions, with the potential to help improve health and reduce costs.
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis
TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ:4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate Scho…
BOCA RATON, Fla.–(BUSINESS WIRE)–Modernizing Medicine, Inc., the creator of the Electronic Medical Assistant® (EMA™), showcases EMA Gastroenterology at Digestive Disease Week Annual Conference in Washington, D.C.
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE. The published article, “Visual Cycle Modulation as an Approach Towa
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today reported financial results for the three-month period ended March 31, 2015. Company Highlights Successfully implanted 19 Argus® II systems in the first quarter of 2015, the highest number for any quarter to date; Net revenue increased 159% to $1.7 millio
LONDON–(BUSINESS WIRE)–Technavio has published a new report on the global capsule endoscope market, which is expected to grow at a CAGR of 11% from 2015-2019.
PORTLAND, Ore.–(BUSINESS WIRE)–Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, announced today that it has entered into a multi-year agreement with global healthcare supplier Perrigo Company plc to promote the ilast® range of products for eyelid hygiene in the United States. “The ilast® brand is an integral part of our portfolio of branded products,” said Patrick Witham, President and CEO of Paragon BioTeck, Inc. “By expanding our promotional efforts to incl
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure